ABRAMS S I ET AL: "Mutant ras epitopes as targets for cancer vaccines", MPSRCH GENBANK, February 1996 (1996-02), XP002949885, (B1)

XUE W ET AL: "Small RNA combination therapy for lung cancer", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 20140826 NATIONAL ACADEMY OF SCIENCES USA, vol. 111, no. 34, 26 August 2014 (2014-08-26), pages E3553-E3561, XP002730537, ISSN: 0027-8424 (B1)

GJERTSEN M K ET AL: "Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation", MPSRCH GENBANK, 25 November 1995 (1995-11-25), XP002949888, (B1)

GOLAN, T. ET AL.: "Journal A phase I trial of a local delivery siRNA against k-ras in combination with chemotherapy for locally advanced pancreatic adenocarcinoma", JOURNAL OF CLINICAL ONCOLOGY, vol. 31, no. 15, 20 May 2013 (2013-05-20), XP002730535, (B1)

HELMUT OETTLE ET AL: "Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer", JAMA, vol. 297, no. 3, 17 January 2007 (2007-01-17), page 267, XP055142608, ISSN: 0098-7484, DOI: 10.1001/jama.297.3.267 cited in the application (B1)

KHLEIF S N ET AL: "A phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors", MPSRCH GENBANK, March 1999 (1999-03), XP002949886, (B1)

MARIANNE K. GJERTSEN ET AL: "Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma", INTERNATIONAL JOURNAL OF CANCER, vol. 92, no. 3, 1 May 2001 (2001-05-01), pages 441-450, XP055116439, ISSN: 0020-7136, DOI: 10.1002/ijc.1205 cited in the application (B1)

SOUKAINA RÉJIBA ET AL: "K-ras oncogene silencing strategy reduces tumor growth and enhances gemcitabine chemotherapy efficacy for pancreatic cancer treatment", CANCER SCIENCE, vol. 98, no. 7, 1 July 2007 (2007-07-01), pages 1128-1136, XP055063526, ISSN: 1347-9032, DOI: 10.1111/j.1349-7006.2007.00506.x (B1)

STRIMPAKOS A S ET AL: "Update on phase I studies in advanced pancreatic adenocarcinoma. hunting in darkness? Highlights from the "2013 ASCO Annual Meeting". Chicago, IL, USA; May 30 - June 4, 2013", JOURNAL OF THE PANCREAS 2013 E.S. BURIONI RICERCHE BIBLIOGRAFICHE ITA, vol. 14, no. 4, 10 July 2013 (2013-07-10), pages 354-358, XP002730534, ISSN: 1590-8577 (B1)

SYNNE WEDÉN ET AL: "Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras", INTERNATIONAL JOURNAL OF CANCER, vol. 128, no. 5, 12 May 2010 (2010-05-12), pages 1120-1128, XP055116455, ISSN: 0020-7136, DOI: 10.1002/ijc.25449 cited in the application (B1)

WIJERMANS P W ET AL: "Severe immunodeficiency in patients treated with fludarabine monophosphate.", EUROPEAN JOURNAL OF HAEMATOLOGY MAY 1993, vol. 50, no. 5, May 1993 (1993-05), pages 292-296, ISSN: 0902-4441 (B1)

WO-A1-00/66153 (B1)

WO-A1-2014/110408 (B1)

WO-A1-92/14756 (B1)

CONROY ET AL.: "FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer", N ENGL J MED, vol. 364, no. 19, 2011, pages 1817-1825, XP002730536, cited in the application (B1)